Art. -Nr.: HY-100003

ML-210

33 Cited Publications

Kundenbewertung

Based on 33 publication(s) in Google Scholar

ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC₅₀ of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 1360705-96-9
Formel: C₂₂H₂₀Cl₂N₄O₄
Molecular Weight:475.32

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

ML-210 Chemical Structure

CAS. Nr.: 1360705-96-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (33)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC₅₀ of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity^[1]^[2].

IC₅₀ & Target

GPX4

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen :

GPX1
GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.3 μM Compound: ML210; 3	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37087895]
ASPC1	IC₅₀	342 nM Compound: ML210	Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
BJ	IC₅₀	107 nM Compound: 2y	Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay	[PMID: 22297109]
Calu-1	IC₅₀	0.9 μM Compound: ML210; 3	Antiproliferative activity against human Calu-1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human Calu-1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37087895]
Calu-1	IC₅₀	630 nM Compound: ML210	Antiproliferative activity against human Calu-1 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human Calu-1 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 36603510]
HCT-116	IC₅₀	>1 μM Compound: ML-210	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
HCT-116	IC₅₀	>10 nM Compound: ML210	Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
HEK-293T	IC₅₀	0.2 μM Compound: ML210; 3	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 37087895]
HEK-293T	IC₅₀	430 nM Compound: ML210	Antiproliferative activity against human HEK293T cells incubated for 24 hrs Antiproliferative activity against human HEK293T cells incubated for 24 hrs	[PMID: 37098297]
HeLa	IC₅₀	0.253 μM Compound: ML-210	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
HT-1080	IC₅₀	0.019 μM Compound: ML210	Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 38838547]
HT-1080	IC₅₀	0.022 μM Compound: ML-210	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
HT-1080	IC₅₀	0.1 μM Compound: ML210; 3	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37087895]
HT-1080	IC₅₀	0.153 μM Compound: ML210	Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 38505849]
HT-1080	IC₅₀	410 nM Compound: ML210	Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 36603510]
HT-1080	IC₅₀	410 nM Compound: ML210	Antiproliferative activity against human HT-1080 cells incubated for 24 hrs Antiproliferative activity against human HT-1080 cells incubated for 24 hrs	[PMID: 37098297]
MCF7	IC₅₀	>20 μM Compound: ML210	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs in presence of Fer-1 by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs in presence of Fer-1 by CCK8 assay	[PMID: 33725632]
MCF7	IC₅₀	0.076 μM Compound: ML210	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 33725632]
MDA-MB-231	IC₅₀	0.02 μM Compound: ML-210	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
MDA-MB-231	IC₅₀	0.021 μM Compound: ML210	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 38838547]
MDA-MB-468	IC₅₀	0.066 μM Compound: ML-210	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
MEF	IC₅₀	0.016 μM Compound: ML-210	Cytotoxicity against mouse MEF cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against mouse MEF cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
NCI-H520	IC₅₀	0.012 μM Compound: ML210	Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo assay	[PMID: 38838547]
NCI-H522	IC₅₀	0.044 μM Compound: ML-210	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
NCI-H522	IC₅₀	33 nM Compound: ML210	Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
NCI-H522	IC₅₀	34.515 μM Compound: ML-210	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days in presence of ferroptosis inhibitor, liproxstatin-1 by methylene blue staining based analysis Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days in presence of ferroptosis inhibitor, liproxstatin-1 by methylene blue staining based analysis	[PMID: 35984756]
U2OS	IC₅₀	0.822 μM Compound: ML-210	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
WI-38	IC₅₀	0.06 μM Compound: ML-210	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]

In Vitro

ML-210 exhibits cell-killing activity across a panel of 821 cancer cell lines (WM88, LOX-IMVI, CJM, U257, CAKI2, A498, HT1080, MC38, PANC02). ML-210 is a prodrug that requires cellular activation to bind GPX4^[1].
ML-210 has IC₅₀s of 71 nM, 272 nM and 107nM for BJeLR (HRAS_V12), BJeH-LT (without HRAS_V12) and DRD cell lines, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1360705-96-9
Appearance Solid
Molecular Weight 475.32
Formel C₂₂H₂₀Cl₂N₄O₄
Color White to light yellow
SMILES

O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)C4=NOC(C)=C4[N+]([O-])=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (33)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nature

7-Dehydrocholesterol dictates ferroptosis sensitivity. [Abstract]

2024 Feb;626(7998):411-418. PMID: 38297130

ML-210 purchased from MedChemExpress. Usage Cited in: Nature. 2024 Feb;626(7998):411-418. [Abstract]

Cell viability of WT and CYP51A1, MSMO1, EBP, SC5D KO HEK293T cells treated with ML210 for 8-10 h.
Autophagy

Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]

2026 Feb 15:1-19. PMID: 41612599
Cell Discov

TGM2-mediated serotonylation of GPX4 confers ferroptosis resistance to promote gastric tumorigenesis. [Abstract]

2026 Apr 28;12(1):30. PMID: 42049702
Cell Discov

Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. [Abstract]

2022 May 3;8(1):40. PMID: 35504898

ML-210 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 May 3;8(1):40. [Abstract]

U2OS cells were treated with ML210 (10 µM; 0.5-8 h) for different time as indicated. O-GlcNAcylation levels were detected by immunoblotting with antibodies against O-GlcNAc and β-actin.
Mol Cell

mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. [Abstract]

2026 Apr 16;86(8):1546-1559.e8. PMID: 41997112
Nat Chem Biol

CGI1746 targets σ1R to modulate ferroptosis through mitochondria-associated membranes. [Abstract]

2024 Jun;20(6):699-709. PMID: 38212578

ML-210 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2024 Jun;20(6):699-709. [Abstract]

The effect of BAPTA-AM (5 μM) on ML210-induced ferroptosis in MDA-MB-468 cells for 6 h.
Biomark Res

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2. [Abstract]

2025 Jan 23;13(1):17. PMID: 39849645

ML-210 purchased from MedChemExpress. Usage Cited in: Biomark Res. 2025 Jan 23;13(1):17. [Abstract]

Cell viability of NCI-H1299 ACSL4^WT or ACSL4^KO cells treated with 2μM ML-210 at the indicated concentrations after 10 h.
Adv Sci (Weinh)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [Abstract]

2026 Mar;13(16):e13310. PMID: 41589654
Adv Sci (Weinh)

GPX4 Inhibitor Resistance and Metastatic Features in Triple-Negative Breast Cancer. [Abstract]

2026 Feb 17:e23198. PMID: 41704007
Adv Sci (Weinh)

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. [Abstract]

2025 Mar;12(12):e2408845. PMID: 39888307
Sci Adv

Metabolic rewiring driven by phosphoglycolate phosphatase deletion inhibits ferroptosis. [Abstract]

2026 May 29;12(22):eaeb2368. PMID: 42213853
Sci Adv

Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. [Abstract]

2025 Aug 15;11(33):eadx6587. PMID: 40815641

ML-210 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Aug 15;11(33):eadx6587. [Abstract]

Viability of WT and TMEM16F KO RMA cells treated with ML210 for 12 hours.
Chem Eng J

2024 Dec 15.
Small

Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification. [Abstract]

2021 Nov;17(47):e2103919. PMID: 34623753
J Immunother Cancer

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma. [Abstract]

2024 Nov 24;12(11):e009805. PMID: 39581704
Cell Death Discov

Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer. [Abstract]

2025 Sep 25;11(1):423. PMID: 40998801
Oncogene

CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in hepatocellular carcinoma. [Abstract]

2026 May;45(16):1411-1424. PMID: 41896589
Oncogene

SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways. [Abstract]

2024 Nov;43(45):3335-3347. PMID: 39306614
Cell Prolif

Glutaminase-1 Mediated Glutaminolysis to Glutathione Synthesis Maintains Redox Homeostasis and Modulates Ferroptosis Sensitivity in Cancer Cells. [Abstract]

2025 Nov;58(11):e70036. PMID: 40259435
J Ethnopharmacol

Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]

2026 Feb 28:357:120890. PMID: 41232632
Biochem Pharmacol

Pharmacological activation of GPX4 by selenomethionine attenuates cisplatin-induced ototoxicity and hearing loss. [Abstract]

2026 Jun:248:117816. PMID: 41698483
Cell Mol Life Sci

Selenium-SelK-GPX4 axis protects nucleus pulposus cells against mechanical overloading-induced ferroptosis and attenuates senescence of intervertebral disc. [Abstract]

2024 Jan 22;81(1):49. PMID: 38252317
Mol Metab

Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization. [Abstract]

2026 May 20:102382. PMID: 42155637
Eur J Pharmacol

Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. [Abstract]

2024 May 15:971:176544. PMID: 38552939
Int Immunopharmacol

Puerarin triggers sensitivity to ferroptosis in glioblastoma cells by activating SIRT3/NCOA4-dependent autophagy. [Abstract]

2025 Mar 6:149:114246. PMID: 39929095
Food Chem Toxicol

Mitophagy contributes to zinc-induced ferroptosis in porcine testis cells. [Abstract]

2023 Sep:179:113950. PMID: 37481227
Am J Cancer Res

SIRT6 drives sensitivity to ferroptosis in anaplastic thyroid cancer through NCOA4-dependent autophagy. [Abstract]

2023 Feb 15;13(2):464-474. PMID: 36895980
World J Surg

Ferroptosis Inducers in Thyroid Cancer. [Abstract]

2023 Feb;47(2):371-381. PMID: 36195678
SSRN

2025 Dec 2.
Seoul National University

2026.
bioRxiv

Genotoxic formaldehyde and lipid aldehydes are sources of DNA damage in keratinocytes. [Abstract]

2025 Nov 14:2025.11.13.688345. PMID: 41292832
bioRxiv

2025 Sep 21.
Ruperto Carola University Heidelberg

2023 Jun 20.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (52.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1038 mL

10.5192 mL

21.0385 mL

5 mM

0.4208 mL

2.1038 mL

4.2077 mL

10 mM

0.2104 mL

1.0519 mL

2.1038 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.

[2]. Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1038 mL	10.5192 mL	21.0385 mL	52.5961 mL
	5 mM	0.4208 mL	2.1038 mL	4.2077 mL	10.5192 mL
	10 mM	0.2104 mL	1.0519 mL	2.1038 mL	5.2596 mL
	15 mM	0.1403 mL	0.7013 mL	1.4026 mL	3.5064 mL
	20 mM	0.1052 mL	0.5260 mL	1.0519 mL	2.6298 mL
	25 mM	0.0842 mL	0.4208 mL	0.8415 mL	2.1038 mL
	30 mM	0.0701 mL	0.3506 mL	0.7013 mL	1.7532 mL
	40 mM	0.0526 mL	0.2630 mL	0.5260 mL	1.3149 mL
	50 mM	0.0421 mL	0.2104 mL	0.4208 mL	1.0519 mL

Keywords

ML-210

33 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ML-210

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Cuproptosis Compound Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ML-210

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (33)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ML-210

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Cuproptosis Compound Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ML-210

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (33)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ML-210 Related Classifications

HY-100003 Related Classifications